Top

CNS Drugs

Published in:

01-09-2006 | Review Article

Buprenorphine-Containing Treatments

Place in the Management of Opioid Addiction

Author: Dr Susan E. Robinson

Published in: CNS Drugs | Issue 9/2006

Abstract

Although the synthetic opioid buprenorphine has been available clinically for almost 30 years, its use has only recently become much more widespread for the treatment of opioid addiction.

The pharmacodynamic and pharmacokinetic profiles of buprenorphine make it unique in the armamentarium of drugs for the treatment of opioid addiction. Buprenorphine has partial µ-opioid receptor agonist activity and is a κ-opioid receptor antagonist; hence, it can substitute for other µ-opioid receptor agonists, yet is less apt to produce overdose reactions or dysphoria. On the other hand, buprenorphine can block the effects of opioids such as heroin (diamorphine) and morphine, and can even precipitate withdrawal in individuals physically dependent upon these drugs. Buprenorphine has significant sublingual bioavailability and a long half-life, making administration on a less than daily basis possible. Furthermore, its discontinuation is associated with only a mild withdrawal syndrome.

Clinical trials have demonstrated that sublingual buprenorphine is effective in both maintenance therapy and detoxification of individuals addicted to opioids. The introduction of a sublingual formulation combining naloxone with buprenorphine further reduces the risk of diversion to illicit intravenous use. Because of its relative safety and lower risk of illegal diversion, buprenorphine has been made available in several countries for treating opioid addiction in the private office setting, greatly enhancing treatment options for this condition.

The use of trade names is for product identification purposes only and does not imply endorsement.

World Health Organization. The selection and use of essential medicines: report of the WHO Expert Committee 2005, including the 14th Model List of Essential Medicines (WHO technical report series, no. 933) [online]. Available from URL: http://www.who.int/medicines [Accessed 2006 Aug 27]

Robinson SE. Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction. CNS Drug Rev 2002 Winter; 8: 377–90PubMedCrossRef

Cowan A. Update on the general pharmacology of buprenorphine. In: Cowan A, Lewis JW, editors. Buprenorphine: combatting drug abuse with a unique opioid. New York: Wiley-Liss, 1995: 31–47

Cowan A, Doxey JC, Harry EJR. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol 1977 Aug; 60: 547–54PubMedCrossRef

Cowan A, Lewis JW, Macfarlane IR. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 1977 Aug; 60: 537–45PubMedCrossRef

Dum EE, Herz A. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br J Pharmacol 1981 Nov; 74: 627–33PubMedCrossRef

Sadé W, Rosenbaun JS, Herz A. Buprenorphine: differential interaction with opiate receptor subtypes in vivo. J Pharmacol Exp Ther 1982 Oct; 223: 157–62

Lufty K, Eitan S, Bryant CD, et al. Buprenorphine-induced anti-nociception is mediated by µ-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci 2003 Nov; 23: 10331–7

Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978 Apr; 35: 601–16CrossRef

10.

Blom Y, Bondessen U, Gunne LM. Effects of buprenorphine in heroin addicts. Drug Alcohol Depend 1987 Sep; 20: 1–7PubMedCrossRef

11.

Preston KL, Liebson IA, Bigelow GE. Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination. J Pharmacol Exp Ther 1992 Apr; 261: 62–71PubMed

12.

Pickworth WB, Johnson RE, Holicky BA, et al. Subjective and physiological effects of intravenous buprenorphine in humans. Clin Pharmacol Ther 1993 May; 53: 570–6PubMedCrossRef

13.

Walsh SL, Preston KL, Bigelow GE, et al. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 1995 Jul; 274: 361–72PubMed

14.

Zacny JP, Conley K, Galinkin J. Comparing the subjective, psychomotor, and physiological effects of intravenous buprenorphine and morphine in healthy volunteers. J Pharmacol Exp Ther 1997 Sep; 282: 1187–97PubMed

15.

Bedi NS, Ray R, Jain R, et al. Abuse liability of buprenorphine: a study among experienced drug users. Ind J Physiol Pharmacol 1998 Jan; 42: 95–100

16.

Preston KL, Bigelow GE. Drug discrimination assessment of agonist-antagonist opioids in humans: a three-choice saline-hydromorphone-butorphanol procedure. J Pharmacol Exp Ther 1994 Oct; 271: 48–60PubMed

17.

Jones HE, Bigelow GE, Preston KL. Assessment of opioid partial agonist activity with a three-choice hydromorphone dose-discrimination procedure. J Pharmacol Exp Ther 1999 Jun; 289: 1350–61PubMed

18.

Hambrook JM, Rance MJ. The interaction of buprenorphine with the opiate receptor: lipophilicity as a determining factor in drug-receptor kinetics. In: Kosterlitz HW, editor. Opiates and endogenous opioid peptides. Amsterdam: Elsevier, 1976: 295–301

19.

Lewis JW. Buprenorphine. Drug Alcohol Depend 1985 Feb; 14: 363–72PubMedCrossRef

20.

Kosten TR, Krystal JH, Charney DS, et al. Opioid antagonist challenges in buprenorphine maintained patients. Drug Alcohol Depend 1990 Feb; 25: 73–8PubMedCrossRef

21.

Nigam AK, Srivastava RP, Saxena S, et al. Naloxone-induced withdrawal in patients with buprenorphine dependence. Addiction 1994 Mar; 89: 317–20PubMedCrossRef

22.

Eissenberg T, Greenwald MK, Johnson RE, et al. Bupre-norphine’s physical dependence potential: antagonist-precipitated withdrawal in humans. J Pharmacol Exp Ther 1996 Feb; 276: 449–59PubMed

23.

Walsh SL, June HL, Schuh KJ, et al. Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology 1995 Jun; 119: 268–76PubMedCrossRef

24.

Fudala PJ, Jaffe JH, Dax EM, et al. Use of buprenorphine in the treatment of opioid addiction: II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther 1990 Apr; 47: 525–34

25.

San L, Cami J, Fernandez T, et al. Assessment and management of opioid withdrawal symptoms in buprenorphine-dependent subjects. Br J Addict 1992 Jan; 87: 55–62PubMedCrossRef

26.

Tracqui A, Kintz P, Ludes B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Anal Toxicol 1998 Oct; 22: 430–4PubMed

27.

Gueye PN, Borron SW, Risede P, et al. Buprenorphine and midazolam act in combination to depress respiration in rats. Toxicol Sci 2002 Jan; 65: 107–14PubMedCrossRef

28.

Kintz P. A new series of 13 buprenorphine-related deaths. Clin Biochem 2002 Oct; 35: 513–6PubMedCrossRef

29.

Pontani RB, Vadlamani NL, Misra AL. Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. Xenobiotica 1985 Apr; 15: 287–97PubMedCrossRef

30.

Holland MJ, Carr KD, Simon EJ. Pharmacokinetics of [3H]-buprenorphine in the rat. Res Commun Chem Path Pharmacol 1989 Apr; 64: 3–16

31.

Ho ST, Wang JJ, Ho W, et al. Determination of buprenorphine by high performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. J Chromatogr 1991 Oct; 570: 339–50PubMedCrossRef

32.

McQuay HJ, Moore RA. Buprenorphine kinetics in humans. In: Cowan A, Lewis JW, editors. Buprenorphine: combatting drug abuse with a unique opioid. New York: Wiley-Liss, 1995: 137–47

33.

Rance MJ, Dickens JM. The influence of drug-receptor kinetics on the pharmacological and pharmacokinetic profiles of buprenorphine. In: Van Ree JM, Terenius L, editors. Characteristics and function of opioids. Amsterdam: Elsevier, 1978: 65–6

34.

Kuhlman JJ, Levine B, Johnson RE, et al. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction 1998 Apr; 93: 549–59PubMedCrossRef

35.

Brewster D, Humphrey MJ, McLeavy MA. The systemic bioavailability of buprenorphine by various routes of administration. J Pharm Pharmacol 1981 Aug; 33: 500–6PubMedCrossRef

36.

Marquet P. Pharmacology of high dose buprenorphine. In: Kintz P, Marquet P, editors. Buprenorphine therapy of opiate addiction. Totowa (NJ): Humana Press, 2002: 1–11CrossRef

37.

Bullingham RE, McQuay HJ, Porter EJ, et al. Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis. Br J Clin Pharmacol 1982 May; 13: 665–73PubMedCrossRef

38.

Weinberg DS, Inturrisi CE, Reidenberg B, et al. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 1988 Sep; 44: 335–42PubMedCrossRef

39.

Kuhlman JJ, Lalani S, Magluilo J, et al. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol 1996 Oct; 20: 369–78PubMed

40.

Mendelson J, Upton RA, Everhart ET, et al. Bioavailability of sublingual buprenorphine. J Clin Pharmacol 1997 Jan; 37: 31–7PubMedCrossRef

41.

Strain EC, Moody DE, Stoller KB, et al. Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. Drug Alcohol Depend 2004 Apr; 74: 37–43PubMedCrossRef

42.

Compton P, Ling W, Moody D, et al. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. Drug Alcohol Depend 2006 Mar 15; 82(1): 25–31PubMedCrossRef

43.

Subutex (buprenorphine)/Suboxone (buprenorphine/naloxone). Product information. Richmond (VA): Reckitt Benckiser Pharmaceuticals Inc, 2002

44.

Ohtani M, Kotaki H, Nishitateno K, et al. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther 1997 Apr; 281: 428–33PubMed

45.

Green MD, King CD, Mojarrabi B, et al. Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A 3. Drug Metab Dispos 1998 Jun; 26: 507–12PubMed

46.

Ohtani M, Kotaki H, Uchino K, et al. Pharmacokinetic analysis of enterohepatic circulation of buprenorphine and its active metabolite, norbuprenorphine, in rats. Drug Metab Dispos 1994 Jan–Feb; 22: 2–7PubMed

47.

Hand CW, Sear JW, Uppington J, et al. Buprenorphine disposition in patients with renal impairment: single and continuous dosing with special reference to metabolites. Br J Anaesth 1990 Mar; 64: 272–82CrossRef

48.

Berson A, Gervais A, Cazals D, et al. Hepatitis after intravenous buprenorphine misuse in heroin addicts. J Hepatol 2001 Feb; 34: 346–50PubMedCrossRef

49.

Berson A, Fau D, Fornacciari R, et al. Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation. J Hepatol 2001 Feb; 34: 261–9PubMedCrossRef

50.

Mello NK, Mendelson JH. Buprenorphine suppresses heroin use by heroin addicts. Science 1980 Feb; 207: 657–9PubMedCrossRef

51.

Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet 1999 Jan; 353: 221–6PubMedCrossRef

52.

West SL, O’Neal KK, Graham CW. A meta-analysis comparing the effectiveness of buprenorphine and methadone. J Subst Abuse 2000 Winter; 12: 405–14PubMedCrossRef

53.

Barnett PG, Rodgers JH, Bloch DA. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 2001 May; 96: 683–90PubMedCrossRef

54.

Heel RC, Brogden RN, Speight TM, et al. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs 1979 Feb; 17: 81–110PubMedCrossRef

55.

Dum EE, Bläsig J, Herz A. Buprenorphine: demonstration of physical dependence liability. Eur J Pharmacol 1981 Mar; 70: 293–300PubMedCrossRef

56.

Schmidt WK, Tam SW, Shotzberger GS, et al. Nalbuphine. Drug Alcohol Depend 1985 Feb; 14: 339–62PubMedCrossRef

57.

Schottenfeld RS, Pakes J, O’Connor P, et al. Thrice-weekly versus daily buprenorphine maintenance. Biol Psychiatry 2000 Jun; 47: 1072–9PubMedCrossRef

58.

Johnson RE, Chutuape MA, Strain EC, et al. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000 Nov; 343: 1290–7PubMedCrossRef

59.

Winger G, Woods JH. Effects of buprenorphine on behaviour maintained by heroin and alfentanil in rhesus monkeys. Behav Pharmacol 1996 Mar; 7: 155–9PubMed

60.

Bickel WK, Stitzer ML, Bigelow GE, et al. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther 1988 Oct; 247: 47–53PubMed

61.

Rosen MI, Wallace EA, McMahon TJ, et al. Buprenorphine: duration of blockade of effects of intramuscular hydromorphone. Drug Alcohol Depend 1994 Apr; 35: 141–9PubMedCrossRef

62.

Comer SD, Collins ED, Fischman MW. Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans. Psychopharmacology 2001 Feb; 154: 28–37PubMedCrossRef

63.

Cheskin LJ, Fudula PJ, Johnson RE. A controlled comparison of buprenorphine and clonidine for acute detoxification of opioids. Drug Alcohol Depend 1994 Oct; 36: 115–21PubMedCrossRef

64.

Strain EC, Preston KL, Liebson IA, et al. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone. J Pharmacol Exp Ther 1995 Feb; 272: 628–38PubMed

65.

Strain EC, Walsh SL, Preston KL, et al. The effects of buprenorphine in buprenorphine-maintained volunteers. Psychopharmacology 1997 Feb; 129: 329–38PubMedCrossRef

66.

Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France [letter]. JAMA 2001 Jan; 285: 45PubMedCrossRef

67.

Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992 May; 267: 2750–5PubMedCrossRef

68.

WHO. Proposal for the inclusion of buprenorphine in the WHO Model List of Essential Medicines. Geneva: Department of Mental Health and Substance Abuse and HIV/AIDS Department, World Health Organization, Oct 2004

69.

Ahmadi J. Methadone vs buprenorphine maintenance for the treatment of heroin-dependent outpatients. J Subst Abuse Treat 2003 Apr; 24: 217–20PubMedCrossRef

70.

Bickel WK, Stitzer ML, Bigelow GE, et al. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther 1988 Jan; 43: 72–8PubMedCrossRef

71.

Fischer G, Gombas W, Eder H. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 1999 Sep; 94: 1337–47PubMedCrossRef

72.

Gerra G, Borella F, Zaimovic A, et al. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend 2004 Jul; 75: 37–45PubMedCrossRef

73.

Kosten TR, Schottenfeld R, Ziedonis D, et al. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis 1993 Jun; 181: 358–64PubMedCrossRef

74.

Ling W, Wesson DR, Charuvastra C, et al. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996 May; 53: 401–7PubMedCrossRef

75.

Mattick RP, Ali R, White JM, et al. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003 Apr; 98: 441–52PubMedCrossRef

76.

Oliveto AH, Feingold A, Schottenfeld R, et al. Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone. Arch Gen Psychiatry 1999 Sep; 56: 812–20PubMedCrossRef

77.

Pani P, Maremmani I, Pirastu R, et al. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend 2000 Jul; 60: 39–50PubMed

78.

Petitjean S, Stohler R, Déglon JJ. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend 2001 Mar; 62: 97–104PubMedCrossRef

79.

Schottenfeld RS, Pakes JR, Oliveto A, et al. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine use. Arch Gen Psychiatry 1997 Aug; 54: 713–20PubMedCrossRef

80.

Strain EC, Stitzer ML, Liebson IA, et al. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 1994 Jul; 151: 1025–30PubMed

81.

Strain EC, Stitzer ML, Liebson IA, et al. Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology 1994 Dec; 116: 401–6PubMedCrossRef

82.

Uehlinger C, Deglon JJ, Livoti S, et al. Comparison of buprenorphine and methadone in the treatment of opioid dependence: Swiss multicentre trial. Eur Addict Res 1998 Oct; 4: 13–8PubMedCrossRef

83.

Kakko J, Svanborg KD, Kreek MJ. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomized, placebo-controlled trial. Lancet 2003 Feb; 361: 662–8PubMedCrossRef

84.

Johnson RE, Eissenberg T, Stitzer ML, et al. Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend 1995 Nov; 40: 27–35PubMedCrossRef

85.

Perez de los Cobos J, Martin S, Etcheberrigaray A, et al. A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of drug dependence. Drug Alcohol Depend 2000 Jun; 59: 223–33PubMedCrossRef

86.

Gowing L, Ali R, White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 2004 Oct; (4): CD002025

87.

Sees KL, Delucchi KL, Masson C, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence. JAMA 2000 Mar; 283: 1303–10PubMedCrossRef

88.

Janiri L, Mannelli P, Persico AM, et al. Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. Drug Alcohol Depend 1994 Oct; 36: 139–45PubMedCrossRef

89.

Kutz I, Reznik V. Rapid heroin detoxification using a single high dose of buprenorphine. J Psychoactive Drugs 2001 Apr-Jun; 33: 191–3PubMedCrossRef

90.

Lintzeris N, Bammer G, Rushworth L, et al. Buprenorphine dosing regime for inpatient heroin withdrawal: a symptom-triggered dose titration study. Drug Alcohol Depend 2003 Jun; 70: 287–94PubMedCrossRef

91.

Palmstierna T. Effects of a high-dose fast tapering buprenorphine detoxification program on symptom relief and treatment retention. J Psychoactive Drugs 2004 Jun; 36: 273–7PubMedCrossRef

92.

Umbricht A, Montoya ID, Hoover DR. Naltrexone shortened opioid detoxification with buprenorphine. Drug Alcohol Depend 1999 Oct; 56: 181–90PubMedCrossRef

93.

Vignau J. Preliminary assessment of a 10-day rapid detoxification programme using high dosage buprenorphine. Eur Addict Res 1998 Oct; 4: 29–31PubMedCrossRef

94.

O’Connor PG, Carroll KM, Shi JM, et al. Three methods of opioid detoxification in a primary care setting: a randomized trial. Ann Intern Med 1997 Oct; 127: 526–30PubMed

95.

Lintzeris N, Bell J, Bammer G, et al. A randomized controlled trial of buprenorphine in the management of short-term ambulatory withdrawal. Addiction 2002 Nov; 97: 1395–404PubMedCrossRef

96.

Amass L, Bickel WK, Higgins ST, et al. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. J Addict Dis 1994; 13: 33–45PubMedCrossRef

97.

Becker AB, Strain EC, Bigelow GE, et al. Gradual dose taper following chronic buprenorphine. Am J Addict 2001 Spring; 10: 111–21PubMedCrossRef

98.

Kosten TR, Kleber HD, Morgan C. Treatment of cocaine abuse with buprenorphine. Biol Psychiatry 1989 Oct; 26: 637–9PubMedCrossRef

99.

Kosten TR, Schottenfeld R, Ziedonis D, et al. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis 1993 Jun; 181: 358–64PubMedCrossRef

100.

Mello NK, Mendelson JH, Bree MP, et al. Buprenorphine and naltrexone effects on cocaine self-administration by rhesus monkeys. J Pharmacol Exp Ther 1990 Sep; 254: 926–39PubMed

101.

Brown EE, Finlay JM, Wong JTF, et al. Behavioral and neurochemical interactions between cocaine and buprenorphine: implications for the pharmacotherapy of cocaine abuse. J Pharmacol Exp Ther 1991 Jan; 256: 119–26PubMed

102.

Spealman RD, Bergman J. Modulation of the discriminative stimulus effects of cocaine by µ and κ opioids. J Pharmacol Exp Ther 1992 May; 261: 607–15PubMed

103.

Schottenfeld RS, Pakes J, Ziedonis D, et al. Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans. Biol Psychiatry 1993 Jul; 34: 66–74PubMedCrossRef

104.

Montoya ID, Gorelick DA, Preston KL, et al. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther 2004 Jan; 75: 34–48PubMedCrossRef

105.

Quigley AJ, Bredemeyer DE, Seow SS. A case of buprenorphine abuse. Med J Aust 1984 Mar; 140: 425–6PubMed

106.

Rainey HB. Abuse of buprenorphine [letter]. N Z Med J 1986 Feb; 99: 72PubMed

107.

O’Connor JJ, Moloney E, Travers R, et al. Buprenorphine abuse among opiate addicts. Br J Addict 1988 Sep; 83: 1085–7PubMedCrossRef

108.

Sakol MS, Stark C, Sykes R. Buprenorphine and temazepam abuse by drug-takers in Glasgow: an increase. Br J Addict 1989 Apr; 84: 439–41PubMedCrossRef

109.

Hammersley R, Lavelle T, Forsyth A. Buprenorphine and temazepam: abuse. Br J Addict 1990 Feb; 85: 301–3PubMedCrossRef

110.

Chowdhury AN, Chowdhury S. Buprenorphine abuse: report from India. Br J Addict 1990 Oct; 85: 1349–50PubMedCrossRef

111.

Arditti J, Bourdon JH, Jean P, et al. Buprenorphine abuse in a series of 50 drug addicts hospitalized at a drug dependence evaluation hospital in Marseille [in French]. Therapie 1992 Nov; 47: 561–2PubMed

112.

Robinson GM, Dukes PD, Robinson BJ, et al. The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand. Drug Alcohol Depend 1993 Jun; 33: 81–6PubMedCrossRef

113.

San L, Torrens M, Castillo C, et al. Consumption of buprenorphine and other drugs among heroin addicts under ambulatory treatment: results from cross-sectional studies in 1988 and 1990. Addiction 1993 Oct; 88: 1341–9PubMedCrossRef

114.

Feeney GF, Fairweather P. Groin tissue necrosis requiring skin graft following parenteral abuse of buprenorphine. Drug Alcohol Rev 2003 Sep; 22: 359–61PubMedCrossRef

115.

Jenkinson RA, Clark NC, Fry CL, et al. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction 2005 Feb; 100: 197–205PubMedCrossRef

116.

Harris DS, Jones RT, Welm S, et al. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend 2000 Dec; 61: 85–94PubMedCrossRef

117.

Harris DS, Mendelson JE, Lin ET, et al. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality. Clin Pharmacokinet 2004; 43: 329–40PubMedCrossRef

118.

Strain EC, Moody DE, Stoller KB, et al. Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. Drug Alcohol Depend 2004 Apr; 74: 37–43PubMedCrossRef

119.

Preston KL, Bigelow GE, Liebson IA. Effects of sublingually given naloxone in opioid-dependent human volunteers. Drug Alcohol Depend 1990 Feb; 25: 27–34PubMedCrossRef

120.

Fudala PJ, Yu E, Macfadden W, et al. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend 1998 Mar; 50: 1–8PubMedCrossRef

121.

Mendelson J, Jones RT. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations; why the 4: 1 ratio for treatment? Drug Alcohol Depend 2003 May; 70 (2S): S29-37

122.

Bell J, Byron G, Gibson A, et al. A pilot study of buprenorphine-naloxone combination tablet (Suboxone®) in treatment of opioid dependence. Drug Alcohol Rev 2004 Sep; 23: 311–7PubMedCrossRef

123.

Fudala PJ, Bridge PT, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003 Sep; 349: 949–58PubMedCrossRef

124.

Jarvis MA, Schnoll SH. Methadone treatment during pregnancy. J Psychoactive Drugs 1994 Apr–Jun; 26: 155–61PubMedCrossRef

125.

Dinges DF, Davis MM, Glass P. Fetal exposure to narcotics: neonatal sleep as a measure of nervous system disturbances. Science 1980 Aug; 209: 619–21PubMedCrossRef

126.

Chasnoff IJ, Burns KA, Burns WJ, et al. Prenatal drug exposure: effects on neonatal and infant growth and development. Neurobehav Toxicol Teratol 1986 Jul–Aug; 8: 357–62PubMed

127.

Hans SL. Maternal opioid use and child development. In: Zagon IS, Slotkin TA, editors. Maternal substance abuse and the developing nervous system. San Diego (CA): Academic Press, 1992: 177–213

128.

Reisinger M. Treatment of four pregnant heroin addicts with buprenorphine: history and outcome. In: Harris LS, editor. Problems of drug dependence, 1995. Proceedings of the 57th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. Rockville (MD): National Institute on Drug Abuse, 1996: 261

129.

Fischer G, Etzersdorfer P, Eder H, et al. Buprenorphine maintenance in pregnant opiate addicts. Eur Addict Res 1998 Oct; 4(1 Suppl.): 32–6PubMedCrossRef

130.

Johnson RE, Jones HE, Jasinski DR, et al. Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend 2001 Jun; 63: 97–103PubMedCrossRef

131.

Eder H, Rupp I, Peternell A, et al. Buprenorphine in pregnancy. Psychiatr Prax 2001 Sep; 28: 267–9PubMedCrossRef

132.

Walter DS, Inturrisi CE. Absorption, distribution, metabolism, and excretion of buprenorphine in animals and humans. In: Cowan A, Lewis JW, editors. Buprenorphine: combatting drug abuse with a unique opioid. New York: Wiley-Liss, 1995: 113–35

133.

Davis DD, Templer DI. Neurobehavioral functioning in children exposed to narcotics in utero. Addict Behav 1988; 13: 275–83PubMedCrossRef

134.

van Baar AL, Fleury P, Soepatmi S, et al. Neonatal behaviour after drug dependent pregnancy. Arch Dis Child 1989 Feb; 64: 235–40PubMedCrossRef

135.

De Cubas MM, Field T. Children of methadone-dependent women: developmental outcomes. Am J Orthopsychiatry 1993 Apr; 63: 266–76PubMedCrossRef

136.

Robinson SE, Guo H, Enters EK, et al. Prenatal exposure to methadone affects central cholinergic neuronal activity in the weanling rat. Brain Res Dev Brain Res 1991 Dec; 64: 183–8PubMedCrossRef

137.

Hutchings DE, Zmitrovich AC, Brake SC, et al. Prenatal administration of methadone using the osmotic minipump: effects on maternal and offspring toxicity, growth, and behavior in the rat. Neurotoxicol Teratol 1992 Jan–Feb; 14: 65–71PubMedCrossRef

138.

Zagon IS, McLaughlin PJ. Opioids and the developing nervous system. In: Zagon IS, Slotkin TA, editors, Maternal substance abuse and the developing nervous system. San Diego (CA): Academic Press, 1992: 241–82

139.

Seatriz JV, Hammer RP. Effects of opiates on neuronal development in the rat cerebral cortex. Brain Res Bull 1993 Mar; 30: 523–7PubMedCrossRef

140.

Robinson SE, Guo H, Spencer RF. Prenatal exposure to methadone delays the development of striatal cholinergic neurons. Brain Res Dev Brain Res 1993 Dec; 76: 239–48PubMedCrossRef

141.

Kunko PM, Smith JA, Wallace MJ, et al. Perinatal methadone exposure produces physical dependence and altered behavioral development in the rat. J Pharmacol Exp Ther 1996 Jun; 277: 1344–51PubMed

142.

Robinson SE, Mo Q, Guo H, et al. Perinatal exposure to methadone affects central cholinergic activity in the weanling rat. Drug Alcohol Depend 1996 Jun; 41: 116–26CrossRef

143.

Robinson SE, Guo H, Maher JR, et al. Postnatal methadone exposure does not prevent prenatal methadone-induced changes in striatal cholinergic neurons. Brain Res Dev Brain Res 1996 Aug; 95: 118–21PubMedCrossRef

144.

Barron S, Chung VM. Prenatal buprenorphine exposure and sexually dimorphic nonreproductive behaviors in rats. Pharmacol Biochem Behav 1997 Oct; 58: 337–43PubMedCrossRef

145.

Wu VW, Schwartz JP, Mo Q, et al. Perinatal opioids reduce striatal nerve growth factor content in rat striatum. Eur J Pharmacol 2001 Mar; 414: 211–4PubMedCrossRef

146.

Robinson SE, Wallace MJ. Effect of perinatal buprenorphine exposure on development in the rat. J Pharmacol Exp Ther 2001 Aug; 298: 797–804PubMed

147.

Robinson SE. Effects of perinatal buprenorphine and methadone exposures on striatal cholinergic ontogeny. Neurotoxicol Teratol 2002 Mar–Apr; 24: 137–42PubMedCrossRef

148.

McCance-Katz EF. Office-based buprenorphine treatment for opioid-dependent patients. Harv Rev Psychiatry 2004 Nov–Dec; 12: 321–38PubMedCrossRef

149.

O’Connor PG, Oliveto AH, Shi JM, et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance abusers versus a methadone clinic. Am J Med 1998 Aug; 105(2): 100–5PubMedCrossRef

150.

Resnik RB, Galanter M, Resnik E, et al. Buprenorphine treatment of heroin dependence (detoxification and maintenance) in a private practice setting. J Addict Dis 2001; 20: 75–83CrossRef

151.

Fiellin DA, Pantalon MV, Pakes JP, et al. Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse 2002 May; 28: 231–41PubMedCrossRef

152.

Ortner R, Jagsch R, Schindler SD, et al. Buprenorphine maintenance: office-based treatment with addiction clinic support. Eur Addict Res 2004; 10: 105–11PubMedCrossRef

153.

Bickel WK, Amass L, Higgins ST, et al. Effects of adding behavioral treatment to opioid detoxification with buprenorphine. J Consult Clin Psychol 1997 Oct; 65: 803–10PubMedCrossRef

154.

Montoya ID, Schroeder JR, Preston KL, et al. Influence of psychotherapy attendance on buprenorphine treatment outcome. J Subst Abuse Treat 2005 Apr; 28: 247–54PubMedCrossRef

155.

Public policy statement on Office-Based Opioid Agonist Treatment (OBOT). J Addict Dis 2005; 24: 153–61CrossRef

156.

Colameco S, Armando J, Trotz C. Opiate dependence treatment with buprenorphine: one year’s experience in a family practice residency setting. J Addict Dis 2005; 24: 25–32PubMedCrossRef

Title: Buprenorphine-Containing Treatments
Place in the Management of Opioid Addiction
Author: Dr Susan E. Robinson
Publication date: 01-09-2006
Publisher: Springer International Publishing
Published in: CNS Drugs / Issue 9/2006
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200620090-00001

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Buprenorphine-Containing Treatments

Place in the Management of Opioid Addiction

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2006

Rufinamide

Rufinamide

Rivastigmine

Methylphenidate and its Isomers

Rivastigmine in Parkinson’s Disease Dementia

Rivastigmine in Parkinson’s Disease Dementia